|国家预印本平台
首页|右美托咪定经鼻给药在临床中的研究进展

右美托咪定经鼻给药在临床中的研究进展

Progress in the application of dexmedetomidine in anesthesia through nasal administration

中文摘要英文摘要

右美托咪定作为α2肾上腺素受体激动剂,通过作用于脑内蓝斑核G蛋白偶联受体和脊髓后角突触后膜上的α2受体,在几乎不引起呼吸抑制的情况下发挥其镇静、镇痛、抗焦虑、降低寒战发生率等作用。与传统的静脉给药途径易引起血流动力学波动等不良后果相比,经鼻给药作为其新兴的临床给药方式之一,在起到与静脉给药相同甚至更优作用的同时,刺激小,起效缓慢而平稳,易被患者接受,近年来逐渐应用广泛。本综述就右美托咪定新的给药方式——经鼻给药,在麻醉中的的应用进展进行综述,探究其作用及影响,以期对临床治疗提供新方向、新思路、新方法。

exmedetomidine is a hepatically eliminated drug ,as an α2-adrenergic receptor agonist, demedetomidine exerts sedative, analgesic, anti-anxiety, and decrease the incidence of chill without causing respiratory depression by acting on the G-protein-coupled receptor in the brain locus locus locus and the postsynaptic membrane a2 receptor in the posterior horn of the spinal cord through traditional intravenous administration, but it also causes hemodynamic fluctuations. In the special population, this effect may be more prominent. In this review, the research progress of demedetomidine intranasal titration, a new administration method for the elderly population, was reviewed, and its influence on the elderly was explored, in order to provide a new direction, mental thinking and new method for clinical treatment of special population.

张蕾、郭青霞

10.12201/bmr.202409.00057

临床医学药学

右美托咪定经鼻药理学麻醉

exmedetomidineNasalPharmacologynesthesia

张蕾,郭青霞.右美托咪定经鼻给药在临床中的研究进展[EB/OL].(2024-08-17)[2025-08-04].https://www.biomedrxiv.org.cn/article/doi/bmr.202409.00057.点此复制

评论